Identification and Evaluation of Besifloxacin as Repurposed Antifungal Drug in Combination With Fluconazole Against Candida albicans
Chemical Biology & Drug Design · 2025
DOI: 10.1111/cbdd.70138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2025. Verfasst von Shuvechha Chakraborty und 4 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Informatics Centre, ICMR-National Institute for Research in Reproductive and Child Health, Mumbai, Maharashtra, India. Hauptthemen laut MEDLINE: Candida albicans, Antifungal Agents, Fluconazole, Azepines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India, Science and Engineering Research Board.
Abstract (Originalsprache)
Emergence of life‐threatening fungal infections like systemic candidiasis concurrently with bacterial infections and limitations of current antifungal therapies warrant the discovery of novel inhibitors. We identified besifloxacin (BS), an FDA‐approved antibacterial, as a potent antifungal inhibitor. A combination of besifloxacin with fluconazole showed a positive synergy (δ = 29.58) resulting in 80% inhibition of microbial growth. BS was able to reduce the MIC of FLC from 2 mg/L to 0.5 mg/L when used in combination. Additionally, in murine systemic Candida infection, BS reduced fungal load by 83% in mice kidneys at a dose of 100 mg/kg/day. The findings demonstrated the antifungal potential of BS, proposing its use in combination therapy with fluconazole to combat resistance through alternative mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomedical Informatics Centre, ICMR-National Institute for Research in Reproductive and Child Health, Mumbai, Maharashtra, India.
- Experimental Animal Facility, ICMR-National Institute for Research in Reproductive and Child Health, Mumbai, Maharashtra, India.
- Indian Council of Medical Research, New Delhi, India.
ORCID-Profile: Shuvechha Chakraborty, Susan Idicula-Thomas
Förderung
- Department of Biotechnology, Ministry of Science and Technology, India
- Science and Engineering Research Board
Zitieren
APA
Chakraborty, S., Pawaskar, A., Metkari, S., Madan, T., & Idicula-Thomas, S. (2025). Identification and Evaluation of Besifloxacin as Repurposed Antifungal Drug in Combination With Fluconazole Against Candida albicans. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70138
Vancouver
Chakraborty S, Pawaskar A, Metkari S, Madan T, Idicula-Thomas S. Identification and Evaluation of Besifloxacin as Repurposed Antifungal Drug in Combination With Fluconazole Against Candida albicans. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70138
BibTeX
@article{Chakraborty2025,
author = {Chakraborty, Shuvechha and Pawaskar, Ameya and Metkari, Siddhanath and Madan, Taruna and Idicula-Thomas, Susan},
title = {Identification and Evaluation of Besifloxacin as Repurposed Antifungal Drug in Combination With Fluconazole Against Candida albicans},
journal = {Chemical Biology & Drug Design},
year = {2025},
doi = {10.1111/cbdd.70138}
}
EUVIMED